scholarly journals HIV Infection in State Hospitals: Case Reports and Long-Term Management Strategies

1990 ◽  
Vol 41 (2) ◽  
pp. 163-166
Author(s):  
Francine Cournos ◽  
Maureen Empfield ◽  
Ewald Horwath ◽  
Howell Schrage
Keyword(s):  
Hiv Infection ◽  
Case Reports ◽  
Management Strategies ◽  
State Hospitals ◽  
Term Management

scholarly journals The Safety and Effect of Local Botulinumtoxin A Injections for Long-Term Management of Chronic Pain in Post-Herpetic Neuralgia: Literature Review and Cases Report Treated with Incobotulinumtoxin A

2021 ◽  
Vol 11 (8) ◽  
pp. 758
Author(s):  
Songjin Ri ◽  
Anatol Kivi ◽  
Jörg Wissel
Keyword(s):  
Chronic Pain ◽  
Neuropathic Pain ◽  
Adverse Events ◽  
Case Reports ◽  
Pain Reduction ◽  
Post Herpetic Neuralgia ◽  
Botulinumtoxin A ◽  
Incobotulinumtoxin A ◽  
Term Management

There are few reports on the safety and effectiveness of long-term botulinumtoxin A (BoNT A) therapy in severe chronic pain of post-herpetic neuralgia (PHN). The literature was searched with the term “neuropathic pain” and “botulinum” on PubMed (up to 29 February 2020). Pain was assessed with the Visual Analogue Scale (VAS) before and after BoNT A therapy. A total of 10 clinical trials and six case reports including 251 patients with PHN were presented. They showed that BoNT A therapy had significant pain reduction (up to 30–50%) and improvement in quality of life. The effect duration seems to be correlated with BoNT A doses injected per injection site. Intervals between BoNT A injections were 10–14 weeks. No adverse events were reported in cases and clinical studies, even in the two pregnant women, whose babies were healthy. The repeated (≥6 times) intra/subcutaneous injections of incobotulinumtoxin A (Xeomin®, Merz Pharmaceuticals, Germany) over the two years of our three cases showed marked pain reduction and no adverse events. Adjunctive local BoNT A injection is a promising option for severe PHN, as a safe and effective therapy in long-term management for chronic neuropathic pain. Its effect size and -duration seem to be depended on the dose of BoNT A injected per each point.

scholarly journals Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn

2002 ◽  
Vol 5 (4) ◽  
pp. 312-328 ◽  
Author(s):  
Ron Goeree ◽  
Bernie J. O'Brien ◽  
Gordon Blackhouse ◽  
John Marshall ◽  
Andrew Briggs ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Management Strategies ◽  
Cost Utility ◽  
Term Management

Enuresis: Myths, Misunderstandings and Solutions

1995 ◽  
Vol 1 (1) ◽  
pp. 74
Author(s):  
Martin Knapp
Keyword(s):  
Management Strategies ◽  
Short Term ◽  
Treatment Facilities ◽  
Conditioning Therapy ◽  
Treatable Condition ◽  
Term Management

Advice on enuresis has been provided by a range of individuals. Many myths and misunderstandings have been responsible for the confusing range of opinions given to those who seek help. Management should be based on an understanding of the physiology of the condition and the established facts about its treatment. There is still a lack of awareness about how effective are the management strategies now proposed by those who base their practise on the extensive research that is now documented. The best results are obtained with conditioning therapy, when this is supervised and supported. There is an important role for 'wetness' alarms in conditioning. There are now body-worn mini-alarms, established by over a decade of use, that are inexpensive and reliable. There is a decreasing role for tricyclic medication. The recently introduced pharmaceutical Minirin (desmopressin) is useful in short-term management to get dryness on social occasions and, in selected individuals, might have a role in long-term control of enuresis, when conditioning has not been effective. There is an important need to provide advice and treatment facilities for all those with enuresis - a treatable condition.

A preliminary study of regeneration in wild populations of threatened endemic Hawaiian palms (Pritchardia; Arecaceae)

2007 ◽  
Vol 13 (1) ◽  
pp. 20 ◽  
Author(s):  
Melany H. Chapin ◽  
Mike Maunder ◽  
Katherine E. Horak
Keyword(s):  
Seed Predation ◽  
Conservation Management ◽  
Management Strategies ◽  
Ecological Change ◽  
Wild Populations ◽  
In The Wild ◽  
Human Colonization ◽  
Preliminary Study ◽  
Term Management

Island floras have been subject to catastrophic changes since human colonization; the Hawaiian Islands exemplify this pattern of species decline and ecological change. Archaeological and historic findings support the former existence of coastal, lowland and interior Pritchardia dominated forests. Wild Pritchardia populations are highly fragmented and exhibit poor or absent regeneration in the wild. This study records seed predation, goat grazing, pig damage, and human harvesting on six wild populations of three species and outlines requirements for the long-term management of wild populations. Only one population of the six studied was found to contain seedlings. Recommended conservation management strategies are outlined.

Long-Term Management of Generalized Pustular Psoriasis with Infliximab: Case Series

2008 ◽  
Vol 12 (4) ◽  
pp. 184-188 ◽  
Author(s):  
Shannon B. Routhouska ◽  
Pranav B. Sheth ◽  
Neil J. Korman
Keyword(s):  
Case Reports ◽  
Case Series ◽  
Term Treatment ◽  
Pustular Psoriasis ◽  
Short Term Treatment ◽  
Long Term Treatment ◽  
Generalized Pustular Psoriasis ◽  
Factor Α ◽  
Term Management

Background: Infliximab, a tumor necrosis factor α antagonist, has recently been shown to be successful for the short-term treatment of generalized pustular psoriasis (GPP) in multiple case reports. Objective: The goal of this case series was to assess the efficacy of the longer-term management of GPP with infliximab. Methods: Three patients with severe GPP were followed to assess the efficacy of long-term treatment with infliximab. Results: Infliximab therapy was more efficacious with infusion every 6 to 8 weeks in combination with methotrexate. Conclusion: Infliximab may be efficacious for some patients for the long-term management of GPP. Maintaining a strict infliximab infusion schedule and concomitant methotrexate therapy may decrease infusion reactions and increase efficacy.

scholarly journals Biologically Based Restorative Management of Tooth Wear

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Martin G. D. Kelleher ◽  
Deborah I. Bomfim ◽  
Rupert S. Austin
Keyword(s):  
Case Reports ◽  
Management Strategies ◽  
Tooth Wear ◽  
Duty Of Care ◽  
Ethical Standards ◽  
Relative Risks ◽  
Long Term Follow Up ◽  
High Level

The prevalence and severity of tooth wear is increasing in industrialised nations. Yet, there is no high-level evidence to support or refute any therapeutic intervention. In the absence of such evidence, many currently prevailing management strategies for tooth wear may be failing in their duty of care to first and foremost improve the oral health of patients with this disease. This paper promotes biologically sound approaches to the management of tooth wear on the basis of current best evidence of the aetiology and clinical features of this disease. The relative risks and benefits of the varying approaches to managing tooth wear are discussed with reference to long-term follow-up studies. Using reference to ethical standards such as “The Daughter Test”, this paper presents case reports of patients with moderate-to-severe levels of tooth wear managed in line with these biologically sound principles.

Irinotecan-associated dysarthria: A single institution case series with management implications in patients with gastrointestinal malignancies

2018 ◽  
Vol 25 (4) ◽  
pp. 980-986 ◽  
Author(s):  
David B Zhen ◽  
Rachel L McDevitt ◽  
Mark M Zalupski ◽  
Vaibhav Sahai
Keyword(s):  
Topoisomerase I ◽  
Case Reports ◽  
Management Strategies ◽  
Case Series ◽  
Single Institution ◽  
Musculoskeletal Discomfort ◽  
Gastrointestinal Malignancies ◽  
Rare Side Effect ◽  
Close Observation

Irinotecan (Camptosar©, CPT-11), a topoisomerase I inhibitor, is a commonly used cytotoxic chemotherapeutic in the treatment of multiple malignancies, particularly of gastrointestinal origin. Dysarthria secondary to irinotecan has been described as a rare side effect in a few case reports with limited data to recommend appropriate management. We describe herein a large single institution experience of patients with gastrointestinal malignancies who experienced dysarthria while being treated with irinotecan-based chemotherapy regimens (FOLFIRINOX or FOLFIRI+/−bevacizumab). Eighteen patients developed neurological manifestations during irinotecan infusion with the majority ( n = 17) developing dysarthria. Patients also experienced other known side effects including cholinergic effects (abdominal bloating, diarrhea, facial flushing, diaphoresis, and rhinorrhea), nausea, fatigue, perioral paresthesia and musculoskeletal discomfort. The dysarthria occurred as early as with the first infusion of irinotecan ( n = 9), but several patients did not develop symptoms until subsequent infusions (range, 1–6). Dose alterations of irinotecan did not obviously impact the reccurrence or severity of dysarthria. Management strategies included close observation, atropine, slower irinotecan infusion rate, and reassurance. Dysarthria resolved without consequence in all patients within hours of completion of the infusion. Oncologists and pharmacists should be aware of irinotecan-associated dysarthria as a rare, self-limited phenomenon with no long-term sequelae, and appropriately counsel patients and infusion nurses to avoid inadvertently withholding potentially beneficial therapy for patients with gastrointestinal malignancies.

Body weight and the management of lymphoedema

2019 ◽  
Vol 24 (12) ◽  
pp. 576-579 ◽  
Author(s):  
Debbie Provan
Keyword(s):  
Risk Factors ◽  
Body Weight ◽  
Weight Management ◽  
Management Strategies ◽  
Overweight And Obesity ◽  
Practical Application ◽  
Ongoing Research ◽  
Term Management ◽  
The Way

Overweight and obesity are known risk factors for the development of lymphoedema, and are also well-recognised factors complicating the management of lymphoedema. However, a degree of uncertainty remains regarding the way in which obesity impacts upon the condition, and there is little detail about the practical application of weight management strategies in the population with lymphoedema. This article provides the background for ongoing research into the association between lymphoedema management and obesity. It is hoped that this research will provide important insights into the long-term management of lymphoedema.

Sign in / Sign up

Export Citation Format

Share Document